These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528 [TBL] [Abstract][Full Text] [Related]
9. Efficient expression and purification of tag-free Epstein-Barr virus EBNA1 protein in Escherichia coli by auto-induction. Mayer CE; Geerlof A; Schepers A Protein Expr Purif; 2012 Nov; 86(1):7-11. PubMed ID: 22944205 [TBL] [Abstract][Full Text] [Related]
10. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication. Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669 [TBL] [Abstract][Full Text] [Related]
11. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription. Liu CD; Lee HL; Peng CW J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781 [TBL] [Abstract][Full Text] [Related]
13. The transcriptional transactivator Tat selectively regulates viral splicing. Jablonski JA; Amelio AL; Giacca M; Caputi M Nucleic Acids Res; 2010 Mar; 38(4):1249-60. PubMed ID: 19966273 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Nuclear Antigen 1 modulates replication of oriP-plasmids by impeding replication and transcription fork migration through the family of repeats. Aiyar A; Aras S; Washington A; Singh G; Luftig RB Virol J; 2009 Mar; 6():29. PubMed ID: 19265546 [TBL] [Abstract][Full Text] [Related]
15. An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, Rch1/importin alpha. Kim AL; Maher M; Hayman JB; Ozer J; Zerby D; Yates JL; Lieberman PM Virology; 1997 Dec; 239(2):340-51. PubMed ID: 9434725 [TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat. Mallon R; Borkowski J; Albin R; Pepitoni S; Schwartz J; Kieff E J Virol; 1990 Dec; 64(12):6282-5. PubMed ID: 2173793 [TBL] [Abstract][Full Text] [Related]
17. Effects of HIV-1 gp120 and TAT-derived microvesicles on endothelial cell function. Hijmans JG; Stockelman K; Levy M; Brewster LM; Bammert TD; Greiner JJ; Connick E; DeSouza CA J Appl Physiol (1985); 2019 May; 126(5):1242-1249. PubMed ID: 30789287 [TBL] [Abstract][Full Text] [Related]
18. The affinity of EBNA1 for its origin of DNA synthesis is a determinant of the origin's replicative efficiency. Lindner SE; Zeller K; Schepers A; Sugden B J Virol; 2008 Jun; 82(12):5693-702. PubMed ID: 18385243 [TBL] [Abstract][Full Text] [Related]
19. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter. Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517 [TBL] [Abstract][Full Text] [Related]
20. E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein-Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions. Boreström C; Forsman A; Rüetschi U; Rymo L J Gen Virol; 2012 May; 93(Pt 5):1065-1075. PubMed ID: 22302879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]